Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers

Introduction: Epidermal growth factor receptor (EGFR) signaling pathway plays a crucial role in the development and progression of lung cancer. We searched for mutations of EGFR pathway genes in non-small cell lung cancers (NSCLCs) and analyzed their relationship with clinicopathologic features. Methods: Mutations of EGFR, ERBB2, ERBB3, ERBB4, KRAS, NRAS, BRAF, PTEN, PIK3CA, LKB1, and AKT1 genes were determined by direct sequencing in 173 surgically resected NSCLCs—56 squamous cell carcinomas (SCCs) and 117 adenocarcinomas (ACs). Results: Of the 173 NSCLCs, a total of 65 mutations were detected in 63 (36.4%) tumors—10 (17.9%) in SCCs and 53 (45.3%) in ACs. Mutations in EGFR pathway genes were significantly more frequent in women and ACs than in women and SCCs (p = 0.02 and p < 0.001, respectively). The mutations occurred in a mutually exclusive pattern. When the genes were divided into three subgroups according to their roles in the signaling cascade, mutations in the EGFR/ERBB2 and KRAS/BRAF genes were more frequent in ACs than in SCCs (p < 0.001 and p = 0.01, respectively). In marked contrast, mutations in the PIK3CA/PTEN were more frequent in SCCs than in ACs (p = 0.002). Furthermore, mutations in the PIK3CA/PTEN genes were more frequent in smokers (p = 0.04). Discussion: Our study demonstrates that mutations in each part of the EGFR pathway were associated with different clinicopathologic features in patients with NSCLCs.

[1]  Dong Sun Kim,et al.  PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.

[2]  Chang Ho Kim,et al.  TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer , 2010, Journal of Korean medical science.

[3]  J. Park,et al.  LKB1 mutations are extremely rare in Korean non-small cell lung cancers. , 2010, Cancer genetics and cytogenetics.

[4]  Jun Yokota,et al.  A gene‐alteration profile of human lung cancer cell lines , 2009, Human mutation.

[5]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[6]  M. Meyerson,et al.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.

[7]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[8]  A. Lièvre,et al.  Mutations and Response to Epidermal Growth Factor Receptor Inhibitors , 2009, Clinical Cancer Research.

[9]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[10]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[11]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[12]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[13]  Chih‐Hsin Yang.  EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. , 2008, Lung cancer.

[14]  M. Moasser,et al.  The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.

[15]  Y. Yatabe,et al.  LKB1 gene mutations in Japanese lung cancer patients , 2007, Cancer science.

[16]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[17]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[18]  J. Park,et al.  EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. , 2007, Cancer genetics and cytogenetics.

[19]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[20]  Y. Bang,et al.  Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.

[21]  W. Park,et al.  Somatic mutations of the ERBB4 kinase domain in human cancers , 2006, International journal of cancer.

[22]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[23]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[24]  J. Minna,et al.  Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[25]  M. Beeram,et al.  Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Elisa Rossi,et al.  Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Aldape,et al.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. , 2005, Human pathology.

[28]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[29]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[30]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[31]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[32]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[33]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[34]  E. Rowinsky.  The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. , 2004, Annual review of medicine.

[35]  J. Minna,et al.  Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non‐small cell lung cancer , 2003, International journal of cancer.

[36]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[37]  Li Mao,et al.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[39]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[40]  J. Yokota,et al.  Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers , 1998, Genes, chromosomes & cancer.

[41]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[42]  J. Minna,et al.  Molecular genetics of lung cancer. , 1988, Annual review of medicine.

[43]  G. Viglietto,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. , 2008, Cell cycle.